Examination of the remission maintenance effect by low dose etanercept after clinical remission in the rheumatoid arthritis.

Examination of the remission maintenance effect by low dose etanercept after clinical remission in the rheumatoid arthritis. - PRESERVATION OF REMISSION MAINTAENANCE BY LOW DOSE ETANERCEPT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013362

Enrollment

Registered

2014-03-06

Start date

2014-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Methotrexate Etanercept

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient of rheumatoid arthritis who is treated by etanercept and who have achieved clinical remission over 6 months.

Exclusion criteria

Exclusion criteria: Patient with a history of the use of the preparation biological by temporary registration. The patient who does not correspond to adaptation of the biologics.

Design outcomes

Primary

Measure	Time frame
Remission maintenance rate (DAS28,SDAI,CDAI) SJC,TJC,CRP,MMP-3,RF,ESR	—

Secondary

Measure	Time frame
Funtional remission rate (HAQ,EQ5D) Radiographic remission rate(mTSS)	—

Countries

Japan

Contacts

Public ContactTakafumi Hagiwara

Takarazuka city hospital Departmentn of Rheumatology

college@katzenauge.sakura.ne.jp0797(87)1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026